Chromosomes and causation of human cancer and leukemia. IX. Prognostic and therapeutic value of chromosomal findings in acute myeloblastic leukemia
Chromosomes and causation of human cancer and leukemia. IX. Prognostic and therapeutic value of chromosomal findings in acute myeloblastic leukemia
复制标题
染色体与人类癌症和白血病的病因。
作者：
M. Sakurai;A. Sandberg
急性髓细胞白血病(AML)患者在开始抗白血病治疗后的中位生存期令人惊讶地短于那些病程中骨髓中从未出现正常中期的患者(AA-患者，1.2个月)，特别是与中期异常和正常的患者(AN-患者，7.2个月)或仅有中期正常的患者(N-患者，9.1个月)相比。在后两组中，大多数70岁以上的患者在治疗后的存活率很低(0.7个月)。与出现症状时相比，这些患者在治疗后的寿命明显缩短，这表明目前的治疗对再生障碍性贫血患者和大多数70岁以上的患者帮助不大。一些AA患者和少数AN患者构成了一组独特的AML患者，在这些患者中，红系和髓系参与了白血病的过程，因此他们实际上受到了红白血病的影响。然而，他们的存活似乎取决于他们的骨髓中是否有任何正常的中期，当白血病患者对治疗有反应时，是否有资格用正常细胞重新填充骨髓。癌症33：1548-1557,1974年。
The median survival after initiation of antileukemic therapy of patients with acute myeloblastic leukemia (AML) was surprisingly short for those patients who never had normal metaphases in their bone marrow during the course of the disease (AA‐patients, 1.2 months), particularly when compared to the survival of patients with both abnormal and normal metaphases (AN‐patients, 7.2 months) or those with only normal metaphases (N‐patients, 9.1 months). Among the latter two groups, the majority of patients over 70 years of age had a very poor survival after therapy (0.7 months). The remarkable shortness of the life span of these patients after therapy, as compared to that from the onset of symptoms, indicates that current therapy is of little help to AA‐patients and most patients over the age of 70. Some of the AA‐patients and a few of the AN‐patients constitute a unique group of AML patients in whom the erythroid and myeloid series are involved by the leukemic process and who are thus actually affected by erythroleukemia. Their survival, however, seems to depend on whether or not they have any normal metaphases in their bone marrow, eligible to repopulate the marrow with normal cells when the leukemic ones have responded to therapy. Cancer 33:1548–1557, 1974.